A Phase 3 interventional study of Dapagliflozin and Dapagliflozin in Type 2 Diabetes, sponsored by AstraZeneca. Completed at 33 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-11.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.
Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 9th largest by enrollment of the 287 interventional ones that give a count, is one of 20 that started in 2010, is one of 72 in phase 3, and was the 109th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18–75 · Men only
JW Pharmaceutical · Sites in Korea, Republic of
Ages 19+
University of California, San Francisco · Sites in United States
Ages 10–21 · Healthy volunteers
RenJi Hospital · Sites in China
Ages 18–65
Lille Catholic University · Sites in France
Ages 18–40
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
293 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 31 · Phase 3 77 · Phase 4 98
First in 1996; this study’s year is marked. 20 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,484 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 100 across the 287 interventional studies. Of the 235 that completed or were terminated, 89 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
155 of 293 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
345 studies in Diabetes Mellitus, Type 2 by AstraZeneca: 13 open now, 15 under way, 9 of them phase 3. Of 325 finished, 149 (46%) have results posted.
Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 12th largest by enrollment of the 280 interventional ones that give a count, is one of 42 that started in 2010, is one of 119 in phase 3, and was the 165th registered.
AstraZeneca’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
7 of the studies testing metformin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02087826Massachusetts General HospitalStudy of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS | 2026-12 |
| NCT06120881University of California, San FranciscoPrecision Dosing of Metformin in Youth With T2D | 2026-12-31 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT07442006JW PharmaceuticalGlycemic Variability of Combination Therapies in T2DM | 2027-03-31 |
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, from their registry updates:
Among AstraZeneca’s 345 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in Asian patients with Type 2 Diabetes who are not well controlled on metformin alone. The safety of this treatment will also be studied.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Dapagliflozin · Drug: Metformin · Drug: Dapagliflozin Placebo · Drug: Pioglitazone
Drug: Dapagliflozin · Drug: Metformin · Drug: Dapagliflozin Placebo · Drug: Pioglitazone
Drug: Metformin · Drug: Dapagliflozin Placebo · Drug: Pioglitazone
Tablets, Oral, 5 mg, Once daily, 24 weeks
Also known as: BMS-512148
Tablets, Oral, 10 mg, Once daily, 24 weeks
Also known as: BMS-512148
Tablets, Oral, 1500-3000 mg, Twice daily, 24 weeks
Also known as: Glucophage®
Tablets, Oral, 0 mg, Once daily, 24 weeks
Tablets, Oral, 15-45 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF])
HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 4, 8, 12, 16, 20, and 24 in the double-blind period.
Time frame: From Baseline to Week 24
Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (Last Observation Carried Forward [LOCF])
Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Fasting plasma glucose was measured as milligrams per deciliter(mg/dL) by a central laboratory. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. FPG measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 1, 2, 4, 8, 12, 16, 20, and 24 in the double-blind period.
Time frame: From Baseline to Week 24
Adjusted Mean Change From Baseline in 2-hour Post Meal Glucose (PMG) (mg/dL) at Week 24 (Last Observation Carried Forward [LOCF])
Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Post Meal Glucose was measured as milligrams per deciliter(mg/dL) by a central laboratory. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. PMG measurements were obtained on Day 1 and week 24 in the double-blind period.
Time frame: From Baseline to Week 24
Adjusted Mean Change From Baseline in Total Body Weight (kg) at Week 24 (Last Observation Carried Forward [LOCF])
Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Adjusted mean change from baseline in total body weight at Week 24 (or the last postbaseline measurement prior to Week 24 if no Week 24 assessment was available was determined. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 1, 2, 4, 8, 12, 16, 20, and 24 of the double-blind period.
Time frame: From Baseline to Week 24
Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])
Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Therapeutic glycemic response is defined as HbA1c \<7.0%. Data after rescue medication was excluded from this analysis. HbA1c was measured as a percent of hemoglobin. Percentage of participants were estimated by modified logistic regression model, adjusted for baseline HbA1c.
Time frame: From Baseline to Week 24
Of 1484 patients enrolled, 554 completed a qualification period. Of these 554 patients, 444 were randomized and received treatment. Of these 444 participants, 409 completed the double-blind treatment period
| Milestone | Placebo + Metformin | Dapagliflozin 5 mg + Metformin | Dapagliflozin 10 mg + Metformin |
|---|---|---|---|
| Started | 145 | 147 | 152 |
| Completed | 128 | 136 | 145 |
| Not completed | 17 | 11 | 7 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 |
| Withdrew: Adverse event | 2 | 1 | 3 |
| Withdrew: Lost to follow-up | 2 | 2 | 0 |
| Withdrew: Withdrawal by subject | 6 | 6 | 1 |
| Withdrew: Non-compliance, not met criteria etc. | 7 | 2 | 2 |
HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 4, 8, 12, 16, 20, and 24 in the double-blind period.
| % of hemoglobin | Placebo + Metformin | Dapagliflozin 5 mg + Metformin | Dapagliflozin 10 mg + Metformin |
|---|---|---|---|
| Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]) | -0.23 ± 0.0622 | -0.82 ± 0.0607 | -0.85 ± 0.0601 |
Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Fasting plasma glucose was measured as milligrams per deciliter(mg/dL) by a central laboratory. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. FPG measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 1, 2, 4, 8, 12, 16, 20, and 24 in the double-blind period.
| mg/dL | Placebo + Metformin | Dapagliflozin 5 mg + Metformin | Dapagliflozin 10 mg + Metformin |
|---|---|---|---|
| Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (Last Observation Carried Forward [LOCF]) | 0.5 ± 2.357 | -21.6 ± 2.308 | -26.6 ± 2.269 |
Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Post Meal Glucose was measured as milligrams per deciliter(mg/dL) by a central laboratory. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. PMG measurements were obtained on Day 1 and week 24 in the double-blind period.
| mg/dL | Placebo + Metformin | Dapagliflozin 5 mg + Metformin | Dapagliflozin 10 mg + Metformin |
|---|---|---|---|
| Adjusted Mean Change From Baseline in 2-hour Post Meal Glucose (PMG) (mg/dL) at Week 24 (Last Observation Carried Forward [LOCF]) | -15.5 ± 4.1548 | -57.8 ± 4.1547 | -64.6 ± 4.0357 |
Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Adjusted mean change from baseline in total body weight at Week 24 (or the last postbaseline measurement prior to Week 24 if no Week 24 assessment was available was determined. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 1, 2, 4, 8, 12, 16, 20, and 24 of the double-blind period.
| kg | Placebo + Metformin | Dapagliflozin 5 mg + Metformin | Dapagliflozin 10 mg + Metformin |
|---|---|---|---|
| Adjusted Mean Change From Baseline in Total Body Weight (kg) at Week 24 (Last Observation Carried Forward [LOCF]) | -0.74 ± 0.1975 | -1.84 ± 0.1935 | -2.56 ± 0.1909 |
Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Therapeutic glycemic response is defined as HbA1c \<7.0%. Data after rescue medication was excluded from this analysis. HbA1c was measured as a percent of hemoglobin. Percentage of participants were estimated by modified logistic regression model, adjusted for baseline HbA1c.
| Percentage of Participants | Placebo + Metformin | Dapagliflozin 5 mg + Metformin | Dapagliflozin 10 mg + Metformin |
|---|---|---|---|
| Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF]) | 17.5 ± 3.136 | 32.9 ± 3.667 | 33.0 ± 3.528 |
Collected over Onset on or after the first date of double-blind treatment and on or prior to the last day of double-blind treatment 24 weeks plus 4 days for non-serious adverse event; plus 30 days for serious adverse event.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo + Metformin | — | 6/145 (4.1%) | 34/145 (23.4%) |
| Dapagliflozin 5 mg + Metformin | — | 3/147 (2%) | 43/147 (29.3%) |
| Dapagliflozin 10 mg + Metformin | — | 3/152 (2%) | 42/152 (27.6%) |
| Event | Placebo + Metformin | Dapagliflozin 5 mg + Metformin | Dapagliflozin 10 mg + Metformin |
|---|---|---|---|
| JOINT INJURYInjury, poisoning and procedural complications | 1/145 | 0/147 | 0/152 |
| SQUAMOUS CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/145 | 0/147 | 0/152 |
| ANGINA UNSTABLECardiac disorders | 1/145 | 0/147 | 0/152 |
| MYOCARDIAL BRIDGINGCongenital, familial and genetic disorders | 1/145 | 0/147 | 0/152 |
| ABDOMINAL HERNIAGastrointestinal disorders | 1/145 | 0/147 | 0/152 |
| PNEUMONIAInfections and infestations | 1/145 | 0/147 | 0/152 |
| BENIGN PROSTATIC HYPERPLASIAReproductive system and breast disorders | 1/145 | 0/147 | 0/152 |
| ASTHMARespiratory, thoracic and mediastinal disorders | 1/145 | 0/147 | 0/152 |
| INFLAMMATORY PSEUDOTUMOURNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/145 | 1/147 | 0/152 |
| LEIOMYOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/145 | 1/147 | 0/152 |
| Event | Placebo + Metformin | Dapagliflozin 5 mg + Metformin | Dapagliflozin 10 mg + Metformin |
|---|---|---|---|
| HYPERLIPIDAEMIAMetabolism and nutrition disorders | 16/145 | 18/147 | 18/152 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 3/145 | 14/147 | 6/152 |
| URINARY TRACT INFECTIONInfections and infestations | 7/145 | 6/147 | 10/152 |
| NASOPHARYNGITISInfections and infestations | 5/145 | 9/147 | 7/152 |
| HYPERURICAEMIAMetabolism and nutrition disorders | 8/145 | 6/147 | 3/152 |
All randomized participants who received at least 1 dose of study medication
| Age, Continuous(Years) | Placebo + Metformin | Dapagliflozin 5 mg + Metformin | Dapagliflozin 10 mg + Metformin | Total |
|---|---|---|---|---|
| Mean | 53.5 ± 9.20 | 53.1 ± 9.09 | 54.6 ± 9.54 | 53.8 ± 9.29 |
| Age, Customized(Participants) | Placebo + Metformin | Dapagliflozin 5 mg + Metformin | Dapagliflozin 10 mg + Metformin | Total |
|---|---|---|---|---|
| Yonger than 65 years | 129 | 132 | 126 | 387 |
| 65 to younger than 75 years | 14 | 13 | 25 | 52 |
| 75 years and older | 2 | 2 | 1 | 5 |
| Sex/Gender, Customized(Participants) | Placebo + Metformin | Dapagliflozin 5 mg + Metformin | Dapagliflozin 10 mg + Metformin | Total |
|---|---|---|---|---|
| Male | 86 | 67 | 88 | 241 |
| Female | 59 | 80 | 64 | 203 |
| Race/Ethnicity, Customized(Participants) | Placebo + Metformin | Dapagliflozin 5 mg + Metformin | Dapagliflozin 10 mg + Metformin | Total |
|---|---|---|---|---|
| Asian Indian | 10 | 11 | 13 | 34 |
| Chinese | 126 | 127 | 129 | 382 |
| Korean | 9 | 9 | 10 | 28 |
The record gives a start of Jun 2010, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2017, 4 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin